Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Lyka Labs Ltd (LYKALABS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500259 NSE: LYKALABS Pharmaceuticals & Drugs | Small Cap | Lyka Labs Share Price
₹66.55 -0.50 (-0.75%)
As on 14-Aug'26 16:59
Lyka Labs Ltd (LYKALABS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500259 NSE: LYKALABS Pharmaceuticals & Drugs | Small Cap | Lyka Labs Share Price
₹66.55 -0.50 (-0.75%)
As on 14-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹241 Cr.
Current Price
₹66.6
52-Week Low / High
₹44 / 110
TTM EPS
₹-8.6
TTM Sales
₹134 Cr.
Book Value per Share
₹24.7
P/E Ratio
0.00
Lower than its 5-year historical median
Industry PE
53.5
Price to Book (P/B)
2.70
Lower than its 5-year historical median
Price to Sales (P/S)
1.80
Lower than its 5-year historical median
EV/EBITDA
126.83
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-31.09%
Underperforms industry median
Return on Capital Employed (ROCE)
-20.28%
Underperforms industry median
Return on Assets (ROA)
-17.77%
Operating Profit Margin
-2%
Net Profit Margin
-26.71%
Gross Profit Margin
-1.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-10.24%
Operating Profit Growth (1 Year)
-
-113.84%
Net Profit Growth (1 Year)
-
-507.7%
Asset Quality
Promoter Holding
58.45%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹53 Cr.
Equity
₹36.2 Cr.
Face Value
₹10
All Time Low / High
₹8.46 / 267.20
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Lyka Labs Ltd a good quality company?
Lyka Labs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Lyka Labs Ltd performance compare with that of its Peers?
Revenue growth of Lyka Labs Ltd vs industry peers?
Lyka Labs Ltd revenue CAGR is 14.20%, compared to the industry median CAGR of 5.75%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Lyka Labs Ltd?
Promoters hold 58.45% of the Lyka Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Lyka Labs Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -0.1% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Lyka Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9% | -1.8% | -0.7% | -20.9% | 4.5% | 47.3% | -1% | 2.5% | 8.5% | -20.3% | - |
| Value Creation Index ⓘ | -0.4 | -1.1 | -1.1 | -2.5 | -0.7 | 2.4 | -1.1 | -0.8 | -0.4 | -2.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 78 | 41.7 | 41.2 | 40.7 | 62.3 | 164 | 80.6 | 106 | 135 | 121 | 134 |
| Sales YoY Gr. | - | -46.6% | -1.2% | -1.1% | 52.8% | 164% | -51% | 32% | 26.6% | -10.2% | - |
| Adj EPS ⓘ | 0.4 | -3.6 | 0.7 | -13.8 | -4.9 | 14 | -2.8 | -0.8 | 2 | -4.7 | -8.6 |
| YoY Gr. | - | -1128.6% | NA | -2036.6% | NA | NA | -119.8% | NA | NA | -332% | - |
| BVPS (₹) ⓘ | 33.4 | 34.1 | 34.8 | 6.6 | 1.5 | 15.5 | 19.2 | 27.3 | 33.9 | 24.3 | 24.7 |
| Adj Net Profit ⓘ | 0.8 | -10.1 | 2 | -39.4 | -13.9 | 40.2 | -8.5 | -2.5 | 7.2 | -16.8 | -31 |
| Cash Flow from Ops. ⓘ | 20.2 | 6.8 | 18.3 | -11.5 | 5.8 | 76.5 | 6.9 | 3.1 | -1.6 | 5.1 | - |
| Debt/CF from Ops. ⓘ | 5.6 | 14.9 | 5 | -12 | 28.1 | 1.7 | 10.4 | 18.4 | -23.5 | 9.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5% | 14.2% | 14.5% | -10.2% | ||||
| Adj EPS ⓘ | -233.5% | NA | NA | -332% | ||||
| BVPSⓘ | -3.5% | 73.6% | 8.1% | -28.6% | ||||
| Share Price | -0.1% | -4.5% | -16% | -33.4% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 1.1 | -11.9 | 2.1 | -67.2 | -120.2 | 164.5 | -14.1 | -2.9 | 6.5 | -16.1 | -35.1 |
| Op. Profit Mgn % ⓘ | 27.9 | -1.2 | 2.2 | -7.9 | 23.2 | 59.3 | 19.4 | 13.7 | 12.9 | -2 | -0.8 |
| Net Profit Mgn % ⓘ | 1 | -24.3 | 4.9 | -96.8 | -22.4 | 24.5 | -10.6 | -2.4 | 5.4 | -13.9 | -23.1 |
| Debt to Equity ⓘ | 1.5 | 1.1 | 0.9 | 7.3 | 36.7 | 2.9 | 1.2 | 0.6 | 0.3 | 0.6 | - |
| Working Cap Days ⓘ | 301 | 602 | 633 | 493 | 230 | 101 | 247 | 214 | 216 | 258 | 88 |
| Cash Conv. Cycle ⓘ | -50 | 91 | 129 | 62 | -25 | -6 | 70 | 65 | 79 | 101 | 17 |
Valuation of Lyka Labs - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 78 | 42 | 41 | 41 | 62 | 164 | 81 | 106 | 135 | 121 |
| Operating Expenses ⓘ + | 56 | 42 | 40 | 44 | 48 | 67 | 65 | 92 | 117 | 123 |
| Operating Profit ⓘ | 22 | -1 | 1 | -3 | 14 | 97 | 16 | 15 | 17 | -2 |
| Operating Profit Margin (%) | 27.9% | -1.2% | 2.2% | -7.9% | 23.2% | 59.3% | 19.4% | 13.7% | 12.9% | -2.0% |
| Other Income ⓘ + | 2 | 2 | 3 | 3 | 2 | 3 | 3 | 2 | 3 | 4 |
| Interest ⓘ | 17 | 8 | 6 | 19 | 26 | 20 | 12 | 5 | 2 | 3 |
| Depreciation ⓘ | 6 | 6 | 4 | 8 | 8 | 15 | 14 | 12 | 7 | 8 |
| Profit Before Tax ⓘ | -1 | -11 | -7 | -55 | -18 | 60 | -13 | -1 | 11 | -33 |
| Tax ⓘ | -0 | -0 | -9 | 0 | -4 | 20 | 0 | 1 | 3 | -1 |
| Profit After Tax | -0 | -11 | 2 | -55 | -14 | 40 | -13 | -2 | 8 | -32 |
| PAT Margin (%) | -0.2% | -26.0% | 4.2% | -135.0% | -23.2% | 24.3% | -16.5% | -2.1% | 5.9% | -26.7% |
| Adjusted EPS (₹) | -0.1 | -3.9 | 0.6 | -19.3 | -5.0 | 13.9 | -4.3 | -0.7 | 2.2 | -9.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 74 | 96 | 98 | 19 | 4 | 44 | 59 | 90 | 121 | 87 | |
| Debt + | 73 | 40 | 91 | 136 | 161 | 82 | 71 | 55 | 34 | 42 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 28 | 21 | 22 | 17 | 12 | 9 | 8 | 11 | 14 | 17 | |
| Others Liabilities ⓘ | 67 | 86 | 27 | 37 | 20 | 74 | 41 | 30 | 24 | 25 | |
| Total Liabilities ⓘ | 242 | 243 | 238 | 209 | 197 | 209 | 179 | 186 | 193 | 171 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 86 | 81 | 76 | 102 | 95 | 90 | 66 | 56 | 85 | 87 | |
| CWIP ⓘ | 24 | 26 | 30 | 26 | 24 | 18 | 16 | 23 | 1 | 2 | |
| Investments ⓘ | 62 | 62 | 62 | 32 | 32 | 32 | 32 | 32 | 15 | 0 | |
| Inventories | 9 | 7 | 6 | 6 | 4 | 8 | 7 | 10 | 12 | 14 | |
| Trade Receivables | 24 | 30 | 30 | 7 | 10 | 18 | 17 | 26 | 40 | 33 | |
| Cash Equivalents | 1 | 0 | 0 | 8 | 7 | 15 | 9 | 6 | 1 | 1 | |
| Others Assets ⓘ | 34 | 35 | 34 | 28 | 24 | 27 | 32 | 34 | 37 | 34 | |
| Total Assets ⓘ | 242 | 243 | 238 | 209 | 197 | 209 | 179 | 186 | 193 | 171 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 20 | 7 | 18 | -11 | 6 | 77 | 7 | 3 | -2 | 5 |
| Cash Flow From Investing Activity ⓘ + | -5 | -3 | -3 | 0 | 0 | -4 | 7 | -9 | -11 | -9 |
| Cash Flow From Financing Activity ⓘ + | -15 | -4 | -16 | 20 | -8 | -63 | -20 | 3 | 8 | 4 |
| Net Cash Flow ⓘ | -0 | -1 | -0 | 8 | -2 | 9 | -7 | -3 | -5 | -0 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -0.27 | -12.78 | 1.79 | -94.98 | -124.71 | 163.37 | -25.69 | -3.04 | 7.49 | -31.09 |
| ROCE (%) | 9.01 | -1.8 | -0.7 | -20.89 | 4.45 | 47.25 | -1.02 | 2.54 | 8.5 | -20.28 |
| Asset Turnover Ratio | 0.36 | 0.18 | 0.17 | 0.18 | 0.31 | 0.81 | 0.42 | 0.58 | 0.71 | 0.67 |
| PAT to CFO Conversion(x) | N/A | N/A | 9 | N/A | N/A | 1.93 | N/A | N/A | -0.25 | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 108.50 | 234 | 265.60 | 162.50 | 48.40 | 30.50 | 78.70 | 73.60 | 89.70 | 110.70 |
| Inventory Days | 34.70 | 71.10 | 58.70 | 52.20 | 29.30 | 13.90 | 34.30 | 28.30 | 29.80 | 39.40 |
| Payable Days | 293.30 | 419.10 | 356.30 | 358.60 | 221.30 | 122.40 | 106.20 | 81.30 | 84.80 | 122.90 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Lyka Labs Ltd FAQs
The current trading price of Lyka Labs on 14-Aug-2026 16:59 is ₹66.55.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Aug-2026 the market cap of Lyka Labs stood at ₹240.6 Cr
The latest P/E ratio of Lyka Labs as of 13-Aug-2026 is 0.00.
The latest P/B ratio of Lyka Labs as of 13-Aug-2026 is 2.70.
The 52-week high of Lyka Labs is ₹109.8 and the 52-week low is ₹44.49.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lyka Labs is ₹134 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Lyka Labs Ltd is a below average quality company.
The key valuation ratios of Lyka Labs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Lyka Labs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Lyka Labs Ltd
Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on December 19, 1985.
The company is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.
Lyka Labs is committed to creating a better tomorrow for India. Maintaining a core competency in Lyophilization, allows Lyka Labs to supply Freeze Dried Drugs in sufficient quantities with the right quality. Lyka strives to manage this business in an ethical and transparent manner.
Lyka has 2 manufacturing facilities in Ankleshwar and Tarapur. There is also an R & D facility based in Chakala, Mumbai, and a corporate head office based in Andheri, Mumbai.
Plant located at Ankleshwar, Gujarat is one of the largest chemical Industrial estates in Asia. Located approx. 10 kms from the city of Bharuch, Gujarat. Ankleshwar is well connected and can be reached by road, rail or air from Mumbai, or by road and rail from Vadodara, or Ahmedabad.
Tarapur Plant is located in the MIDC Industrial Estate in Tarapur, District Thane, Maharashtra. Located approximately 80 kms from Mumbai City, and well connected by rail and road to Mumbai.
Different business lines of the company:
- Contract Manufacturing - Lyka undertakes manufacturing activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire manufacturing process, from sourcing of raw materials to manufacture to packaging, although Lyka also offers job work services where the raw materials are sourced by the client company. Their manufacturing processes are in line with world over best practices, as demonstrated by the ISO 9001:2002 Certification
- Hospital Division - LYKA has forayed into marketing of products into hospitals/ institutions. To begin with, it has introduced a range of anti-infectives, which include systemic antimalarial, antifungal and antibacterials for serious infections. Apart from this, it has also introduced anesthetics, anti-ulcerants and steroid in parenteral dosage forms. On the anvil is the expansion of the range of the products in the above therapeutic segments as well as in the new therapeutic segments. The company also has plan to introduce products in solid dosage forms for hospitals / institutions.
- Lyka Animal Health Care - Lyka Animal Healthcare Division within a short period has made strong presence in Indian Veterinary market with their quality innovative products. The animal healthcare division is managed and headed by veterinary professional with strong and dedicated team of field and in-house persons.
- Generics - When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. Lyka markets branded generic products in the form of: -Tablets -Capsules -Ointments -Syrups Dry Powder and Liquids
- Lyka BDR- Lyka manufactures and sells products to its Joint Venture company Lyka BDR. Lyka BDR is the largest seller of human and veterinary products in Sudan
Product range of the company includes:
- Ampholyn Inj.
- Hydrolin Inj.
- Lyom Inj.
- Lypan Inj.
- Lypitaz Inj. 2.25g
- Lypitaz Inj. 4.5g
- Lyrab Inj.
- Lysunate Inj.
- Lysunate Tabs
- Lyvec Inj.
- Merojet Inj. 500mg
- Merojet Inj.1000mg
- Stropaz Inj.
- Thiolyn Inj. 500mg
- Thiolyn Inj.1000mg
- Vancolym Inj.
- Xolycef - SB Inj.
- Xolycef - TZ Inj.
- Xolycef Inj. 1000mg
- Zimtaz Inj.
Achievements/ recognition:
- ISO 9001:2000 certified
- Recognized as in-house R&D Centre by Government of India, Ministry of Science & Technology, Department of Scientific and Industrial Research.
- In 2011 the company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
